Insulin icodec/Semaglutide

依柯胰岛素/司美格鲁肽

Report date: 2026/03/09 20:02:04

Base Information

Drug NameInsulin icodec/Semaglutide
Drug Alias NameIcoSema依柯胰岛素司美格鲁肽KyinsuIcoSema诺和杰 +[7] 
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsInsulin receptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2025/11/24
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsYes Insulin icodecSemaglutide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk Pharma LtdNovo Nordisk A/SNovo Nordisk (China)Pharmaceuticals Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A